BioXcel Therapeutics, Inc. CEO and President Vimal Mehta Granted Restricted Stock Units

On August 1, 2025, Vimal Mehta, the CEO and President of BioXcel Therapeutics, Inc., was granted 18,000 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the company's Common Stock. The RSUs are set to vest 100% on or within thirty days of 9 months from the Grant Date, which is August 1, 2025. This vesting is contingent on Mehta's continued employment with BioXcel Therapeutics or one of its subsidiaries on the vesting date. The transaction was reported under Form 4, indicating a change in beneficial ownership. The RSUs were granted at a price of $0 per share, and following the transaction, Mehta owns 18,000 shares of the company's Common Stock.